JonesTrading analyst Soumit Roy maintained a Buy rating on Day One Biopharmaceuticals (DAWN – Research Report) today and set a price target of $30.00.
Soumit Roy has given his Buy rating due to a combination of factors including the financial adjustments made to Day One Biopharmaceuticals’ projected R&D expenses for 2025, which have resulted in an improved estimated EPS for the fiscal year. The company has a strong cash position of approximately $531.7 million, which supports its operational and developmental activities.
The valuation analysis, which incorporates DCF, NPV, and PE methodologies, suggests a price target of $30, reflecting a potential $1 billion in peak sales by 2032. Key risks include potential treatment discontinuation rates and adverse events that could affect trial progress. However, the company’s strategic positioning and financial health underpin the Buy recommendation.
Roy covers the Healthcare sector, focusing on stocks such as Chimerix, Day One Biopharmaceuticals, and Oric Pharmaceuticals. According to TipRanks, Roy has an average return of -23.4% and a 16.73% success rate on recommended stocks.
In another report released on March 4, J.P. Morgan also maintained a Buy rating on the stock with a $34.00 price target.